Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease

Expert Opinion on Drug Safety

Volumn 8, Issue 2, 2009, Pages 145-153

  Agarwal, Anil K ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Anemia; CKD; Darbepoetin alfa

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; THEOPHYLLINE; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ABDOMINAL PAIN; ACCESS HEMORRHAGE; ACCESS INFECTION; ACUTE HEART INFARCTION; ANEMIA; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTHRALGIA; ASTHENIA; BACKACHE; BLOOD PRESSURE MONITORING; BLOOD TRANSFUSION; CARDIOVASCULAR FUNCTION; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CONSTIPATION; CONVULSION; CREUTZFELDT JAKOB DISEASE; DIARRHEA; DISEASE TRANSMISSION; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EXTRAMEDULLARY HEMATOPOIESIS; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUID OVERLOAD; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPOTENSION; INCIDENCE; INFECTION RISK; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; KIDNEY FUNCTION; LIMB PAIN; MORTALITY; MUSCLE SPASM; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; POLYCYTHEMIA; PURE RED CELL ANEMIA; RASH; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; STROKE; SURVIVAL; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; VASCULAR ACCESS THROMBOSIS; VIRUS INFECTION; VOMITING; CHRONIC KIDNEY FAILURE; DOSE RESPONSE; DRUG ADMINISTRATION;

ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBINS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 66949156902     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330902793031     Document Type: Review

References (50)

1. Eschbach JW, Varma A, Stivelman JC. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia? Nephrol Dial Transplant 2002;17(Suppl 5):2-7
2. Macdougall IC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int 2001;78(Suppl):S67-72 (Pubitemid 32144073)
3. Klang B, Bjorvell H, Clyne N. Quality of life in predialytic uremic patients. Qual Life Res 1996;5:109-116 (Pubitemid 26100508)
4. Mann JF. What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 1999;14(Suppl 2):29-36
5. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003;108:2154-2169 (Pubitemid 37337595)
6. Pereira AA, Sarnak MJ. Anemia as a risk factor for cardiovascular disease. Kidney Int 2003;64:S32-9; doi:10.1046/j.1523-1755.64.s87.6.x. (Pubitemid 37315505)
7. Locatelli F, Conte F, Marcelli D. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity: the experience of the lombardy dialysis registry. Nephrol Dial Transplant 1998;13:1642-1644 (Pubitemid 28306788)
8. Collins AJ, Li S, St Peter W, et al. Death, hospitalisation, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001;2465-2473 (Pubitemid 33021125)
9. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-299 • Discussion of pharmacokinetic profile of DA. (Pubitemid 36407605)
10. MacDougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-2395 (Pubitemid 29501473)
11. Padhi D, Liyun N, Cooke B, et al. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006;45:503-510
12. Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Bio Chem 2006;281:2024-2032 (Pubitemid 43845790)
13. Aranesp Package. ©2001-2008 Amgen, Inc. v19. Revised: 08/2008
14. Cournoyer D, Toffelmire EB, Wells GA, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004;15:2728-2734 • An article discussing epidemiology of PRCA. (Pubitemid 41103380)
15. Jacob A, Sandu K, Nicholas J, et al. Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant 2006;21:2963-2965 (Pubitemid 44542259)
16. Howman R, Kulkarni H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. Nephrol Dial Transplant 2007;22:1462-1464 (Pubitemid 47072237)
17. MacDougall IC, Casadevall N, Stead RB, et al. Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with Hematide, a novel, synthetic, peptide-based erythropoietin receptor agonist. Nephrology 2008;13(Suppl 1):A6. A report of hematide for treatment of erythropoietin induced PRCA.
18. Available from: www.emea.europa.eu/humandocs/pdfs/EPAR/aranesp/129901en6. pdf.
19. Vanrenterghem Y, Barany P, Mann JFE, et al. Randomized trial of darbepoetin alfa for treatment of renal anaemia at a reduced dosing frequency compared with rHuEpo in dialysis patients. Kidney Int 2002;62:2167-2175 (Pubitemid 35366172)
20. Brunkhorst R, Bommer J, Braun J, et al. Darbepoetin alfa effectively maintains hemoglobin concentration at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004;19:1224-1230 (Pubitemid 38655907)
21. Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patient with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003;18:362-369 (Pubitemid 36181689)
22. MacDougall IC, Matcham J, Gray SJ. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 2003;18:576-581 (Pubitemid 36305665)
23. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:110-118 (Pubitemid 34701218)
24. Braun J. Darbepoetin alfa administered once every 4 weeks maintains hemoglobin levels in patients with chronic kidney disease (CKD) receiving dialysis. Nephrol Dial Transplant 2002;17(Suppl 12):136
25. Jadoul M, Vanrenterghem Y, Foret M, et al. Darbepoetin alfa administered once monthly maintains hemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 2004;19:898-903 (Pubitemid 38455662)
26. Coyne D, Ling BN, Toto R, et al. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant human erythropoietin. J Am Soc Nephrol 2000;11:3029A
27. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741-747 (Pubitemid 32678918)
28. Suranyi MG, Lindberg JS, Navarro J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003;23:106-111 (Pubitemid 36164604)
29. Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004;24:453-460 (Pubitemid 39279389)
30. Hertel J, Locay H, Scarlata D, et al. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once weekly recombinant human erythropoietin: results from STAAR. Am J Nephrol 2006;26:149-156 (Pubitemid 43882399)
31. Agarwal AK, Silver MR, Reed JE, et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Int Med 2006;260:577-585 (Pubitemid 44772378)
32. Silver MR, Agarwal A, Krause M, et al. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease. Am J Geriatr Pharmacother 2008;6(2):49-60
33. Julian BA, Gaston RS, Barker CV, et al. Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis. Kidney Int 1994;46:139701403 (Pubitemid 24330720)
34. Cruz DN, Perazella MA, Abu-Alfa AK, et al. Angiotensin onverting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? Am J Kid Dis 1996;28:535-540
35. Vereerstraeten A, Gastaldello K, Gervy C, et al. High hematocrit in hemodialysis patients can be controlled by theophylline administration. Nephrol Dial Transplant 1994;9:189-191 (Pubitemid 24064686)
36. Lin AC, Goldwasser E, Bernard EM, et al. Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 1990;161:348-351 (Pubitemid 20056672)
37. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590 • The Normal Hematocrit Study of anemia correction in hemodialysis patients with heart failure. (Pubitemid 28385655)
38. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098 • A study of epoetin a in CKD showing higher mortality with correction of anemia to a higher goal. (Pubitemid 44749317)
39. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084 • A study comparing impact of using epoetin β to correct hb to lower and higher hb goals, showing no difference in CV outcomes, but increased risk of progression to dialysis. (Pubitemid 44749316)
40. Mix T, Brenner R, Cooper M, et al. Rationale - trial to reduce cardiovascular events with aranesp therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005;149:408-413 • An ongoing study of DA treatment compared to placebo treatment of anemic patients with CKD and diabetes mellitus to compare effect on CV and renal outcomes. (Pubitemid 40585402)
41. Kilpatrick RD, Critchlow CW, Fishbane SW, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1077-1083
42. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-798
43. Zhang YI, Thamer M, Stefanak K, et al. Epoetin requirements predict mortality in hemodilaysis patients. Am J Kid Dis 2004;44:866-876 (Pubitemid 39445919)
44. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191
45. FDA Perspectives on erythropoiesis-stimulating agents (ESAs) for anemia of chronic renal failure: hemoglobin target and dose optimization. Unger E, 2007. Available from: http://www.fda.gov/OHRMS/DOCKETS/AC/07/slides/2007-4315s1- 10-FDA-Unger.ppt [Accessed 1 April 2009]
46. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kid Dis 2008;52:727-736
47. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-1210
48. Yang W, Israni RK, Brunelli SM, et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007;18:3164-3170 (Pubitemid 350223976)
49. Brunelli SM, Lynch KE, Ankers ED, et al. Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1733-1740
50. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. JASN Expr (Published on 31 January 2007) The DRIVE study of iron treatment in hemodialysis patients.